Prot #CLCI699C2201: A Proof-of Concept, Open-Label, Forced Titration, Multi-Center Study to Assess the Safety/Tolerability and Efficacy of 10-Weeks Treatment of LCI699 Followed by a 12 Week Treatment Period in Patients with Cushing's Disease.

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/1210/31/20

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CLCI699C2201)